275 related articles for article (PubMed ID: 16998649)
1. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M; Fox C; Maidment I; McShane R
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
[TBL] [Abstract][Full Text] [Related]
3. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension.
Oertel W; Poewe W; Wolters E; De Deyn PP; Emre M; Kirsch C; Hsu C; Tekin S; Lane R
Drug Saf; 2008; 31(1):79-94. PubMed ID: 18095748
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine for dementia associated with Parkinson's disease.
Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
[TBL] [Abstract][Full Text] [Related]
5. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.
Devos D; Moreau C; Maltête D; Lefaucheur R; Kreisler A; Eusebio A; Defer G; Ouk T; Azulay JP; Krystkowiak P; Witjas T; Delliaux M; Destée A; Duhamel A; Bordet R; Defebvre L; Dujardin K
J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):668-74. PubMed ID: 24218528
[TBL] [Abstract][Full Text] [Related]
6. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
[TBL] [Abstract][Full Text] [Related]
7. Cholinesterase inhibitors for Parkinson's disease dementia.
Maidment I; Fox C; Boustani M
Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
[TBL] [Abstract][Full Text] [Related]
8. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM
Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467
[TBL] [Abstract][Full Text] [Related]
9. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
[TBL] [Abstract][Full Text] [Related]
10. Rivastigmine and Parkinson dementia complex.
Moretti R; Torre P; Vilotti C; Antonello RM; Pizzolato G
Expert Opin Pharmacother; 2007 Apr; 8(6):817-29. PubMed ID: 17425477
[TBL] [Abstract][Full Text] [Related]
11. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences.
Emre M; Cummings JL; Lane RM
J Alzheimers Dis; 2007 Jul; 11(4):509-19. PubMed ID: 17656830
[TBL] [Abstract][Full Text] [Related]
12. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
Weintraub D; Somogyi M; Meng X
Am J Alzheimers Dis Other Demen; 2011 Sep; 26(6):443-9. PubMed ID: 22009228
[TBL] [Abstract][Full Text] [Related]
13. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.
Ravina B; Putt M; Siderowf A; Farrar JT; Gillespie M; Crawley A; Fernandez HH; Trieschmann MM; Reichwein S; Simuni T
J Neurol Neurosurg Psychiatry; 2005 Jul; 76(7):934-9. PubMed ID: 15965198
[TBL] [Abstract][Full Text] [Related]
14. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
15. Rivastigmine in Parkinson's disease dementia.
Chitnis S; Rao J
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
[TBL] [Abstract][Full Text] [Related]
16. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living.
Olin JT; Aarsland D; Meng X
Dement Geriatr Cogn Disord; 2010; 29(6):510-5. PubMed ID: 20523050
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia.
Schmitt FA; Farlow MR; Meng X; Tekin S; Olin JT
CNS Neurosci Ther; 2010 Dec; 16(6):330-6. PubMed ID: 20950329
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
Emre M; Poewe W; De Deyn PP; Barone P; Kulisevsky J; Pourcher E; van Laar T; Storch A; Micheli F; Burn D; Durif F; Pahwa R; Callegari F; Tenenbaum N; Strohmaier C
Clin Neuropharmacol; 2014; 37(1):9-16. PubMed ID: 24434526
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
Wesnes K
Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707
[TBL] [Abstract][Full Text] [Related]
20. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
Cummings JL; Koumaras B; Chen M; Mirski D;
Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]